91 related articles for article (PubMed ID: 14712488)
1. Human papillomavirus (HPV) type 16-specific CD8+ T cell responses in women with high grade vulvar intraepithelial neoplasia.
Todd RW; Roberts S; Mann CH; Luesley DM; Gallimore PH; Steele JC
Int J Cancer; 2004 Mar; 108(6):857-62. PubMed ID: 14712488
[TBL] [Abstract][Full Text] [Related]
2. Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia.
Todd RW; Steele JC; Etherington I; Luesley DM
Gynecol Oncol; 2004 Jan; 92(1):167-74. PubMed ID: 14751153
[TBL] [Abstract][Full Text] [Related]
3. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses.
Bourgault Villada I; Moyal Barracco M; Ziol M; Chaboissier A; Barget N; Berville S; Paniel B; Jullian E; Clerici T; Maillère B; Guillet JG
Cancer Res; 2004 Dec; 64(23):8761-6. PubMed ID: 15574788
[TBL] [Abstract][Full Text] [Related]
5. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
6. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
[TBL] [Abstract][Full Text] [Related]
7. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
[TBL] [Abstract][Full Text] [Related]
8. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment.
van Poelgeest MI; van Seters M; van Beurden M; Kwappenberg KM; Heijmans-Antonissen C; Drijfhout JW; Melief CJ; Kenter GG; Helmerhorst TJ; Offringa R; van der Burg SH
Clin Cancer Res; 2005 Jul; 11(14):5273-80. PubMed ID: 16033846
[TBL] [Abstract][Full Text] [Related]
9. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.
Bourgault Villada I; Moyal Barracco M; Berville S; Bafounta ML; Longvert C; Prémel V; Villefroy P; Jullian E; Clerici T; Paniel B; Maillère B; Choppin J; Guillet JG
Clin Exp Immunol; 2010 Jan; 159(1):45-56. PubMed ID: 19843089
[TBL] [Abstract][Full Text] [Related]
11. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
[TBL] [Abstract][Full Text] [Related]
12. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
Tong WW; Shepherd K; Garland S; Meagher A; Templeton DJ; Fairley CK; Jin F; Poynten IM; Zaunders J; Hillman RJ; Grulich AE; Kelleher AD; Carr A;
J Infect Dis; 2015 Feb; 211(3):405-15. PubMed ID: 25139018
[TBL] [Abstract][Full Text] [Related]
14. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy.
Abdel-Hady ES; Martin-Hirsch P; Duggan-Keen M; Stern PL; Moore JV; Corbitt G; Kitchener HC; Hampson IN
Cancer Res; 2001 Jan; 61(1):192-6. PubMed ID: 11196160
[TBL] [Abstract][Full Text] [Related]
15. Detection of CD4(+)- and CD8(+)-T-cell responses to human papillomavirus type 1 antigens expressed at various stages of the virus life cycle by using an enzyme-linked immunospot assay of gamma interferon release.
Steele JC; Roberts S; Rookes SM; Gallimore PH
J Virol; 2002 Jun; 76(12):6027-36. PubMed ID: 12021335
[TBL] [Abstract][Full Text] [Related]
16. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
[TBL] [Abstract][Full Text] [Related]
18. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model.
Ahn WS; Bae SM; Kim TY; Kim TG; Lee JM; Namkoong SE; Kim CK; Sin JI
Hum Gene Ther; 2003 Oct; 14(15):1389-99. PubMed ID: 14577920
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.
Trimble CL; Clark RA; Thoburn C; Hanson NC; Tassello J; Frosina D; Kos F; Teague J; Jiang Y; Barat NC; Jungbluth AA
J Immunol; 2010 Dec; 185(11):7107-14. PubMed ID: 21037100
[TBL] [Abstract][Full Text] [Related]
20. Integration of HPV-16 and HPV-18 DNA in vulvar intraepithelial neoplasia.
Hillemanns P; Wang X
Gynecol Oncol; 2006 Feb; 100(2):276-82. PubMed ID: 16300821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
